Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

NCT04443088 is registered in ClinicalTrials.gov with Shenzhen Ionova Life Sciences Co., Ltd. as lead sponsor.

NCT NCT04443088
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04443088 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Lead sponsor
Shenzhen Ionova Life Sciences Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
June 26, 2020
Completion date
December 31, 2026
Enrollment
78 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, cancer metastatic, solid carcinoma, solid tumor, adult, solid tumor, unspecified, adult, tumor, solid